Literature DB >> 18973759

Epoxyeicosatrienoic acid prevents postischemic electrocardiogram abnormalities in an isolated heart model.

S N Batchu1, E Law, D R Brocks, J R Falck, J M Seubert.   

Abstract

Cytochrome P450 epoxygenases metabolize arachidonic acid (AA) to epoxyeicosatrienoic acids (EETs) which are in turn converted to dihydroxyeicosatrienoic acids (DHETs) by soluble epoxide hydrolase (sEH). The main objective of this study was to investigate the protective effects of EETs following ischemic injury using an ex vivo electrocardiogram (EKG) model. Hearts from C57Bl/6, transgenic mice with cardiomyocyte-specific overexpression of CYP2J2 (Tr) and wildtype (WT) littermates were excised and perfused with constant pressure in a Langendorff apparatus. Electrodes were placed superficially at the right atrium and left ventricle to assess EKG waveforms. In ischemic reperfusion experiments hearts were subjected to 20 min of global no-flow ischemia followed by 20 min of reperfusion (R20). The EKG from C57Bl/6 hearts perfused with 1 microM 14,15-EET showed less QT prolongation (QTc) and ST elevation (STE) (QTc=41+/-3, STE=2.3+/-0.3; R20: QTc=42+/-2 ms, STE=1.2+/-0.2mv) than control hearts (QTc=36+/-2, STE=2.3+/-0.2; R20: QTc=53+/-3 ms; STE=3.6+/-0.4mv). Similar results of reduced QT prolongation and ST elevation were observed in EKG recording from CYP2J2 Tr mice (QTc=35+/-1, STE=1.9+/-0.1; R20: QTc=38+/-4 ms, STE=1.3+/-0.2mv) compared to WT hearts. The putative epoxygenase inhibitor MS-PPOH (50 microM) and EET antagonist 14,15-EEZE (10 microM) both abolished the cardioprotective response, implicating EETs in this process. In addition, separate exposure to the K(ATP) channel blockers glibenclamide (1 microM) and HMR1098 (10 microM), or the PKA protein inhibitor H89 (50 nM) during reperfusion abolished the improved repolarization in both the models. Consistent with a role of PKA, CYP2J2 Tr mice had an enhanced activation of the PKAalpha regulatory II subunit in plasma membrane following IR injury. The present data demonstrate that EETs can enhance the recovery of ventricular repolarization following ischemia, potentially by facilitating activation of K(+) channels and PKA-dependent signaling.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18973759     DOI: 10.1016/j.yjmcc.2008.09.711

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  26 in total

Review 1.  Use of metabolomic profiling in the study of arachidonic acid metabolism in cardiovascular disease.

Authors:  Ning Li; Jun-Yan Liu; Hong Qiu; Todd R Harris; Padmini Sirish; Bruce D Hammock; Nipavan Chiamvimonvat
Journal:  Congest Heart Fail       Date:  2011-01-27

2.  Activity, inhibition, and induction of cytochrome P450 2J2 in adult human primary cardiomyocytes.

Authors:  Eric A Evangelista; Rüdiger Kaspera; Nahush A Mokadam; J P Jones; Rheem A Totah
Journal:  Drug Metab Dispos       Date:  2013-09-10       Impact factor: 3.922

3.  Cardioprotective effect of a dual acting epoxyeicosatrienoic acid analogue towards ischaemia reperfusion injury.

Authors:  S N Batchu; S B Lee; R S Qadhi; K R Chaudhary; H El-Sikhry; R Kodela; J R Falck; J M Seubert
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

4.  Development of a high throughput cell-based assay for soluble epoxide hydrolase using BacMam technology.

Authors:  Wensheng Xie; Xiaoyan Tang; Quinn Lu; Robert S Ames; Steven J Ratcliffe; Hu Li
Journal:  Mol Biotechnol       Date:  2010-07       Impact factor: 2.695

5.  Enzymatic and free radical formation of cis- and trans- epoxyeicosatrienoic acids in vitro and in vivo.

Authors:  Theresa Aliwarga; Brianne S Raccor; Rozenn N Lemaitre; Nona Sotoodehnia; Sina A Gharib; Libin Xu; Rheem A Totah
Journal:  Free Radic Biol Med       Date:  2017-07-19       Impact factor: 7.376

Review 6.  Soluble epoxide hydrolase inhibitors and heart failure.

Authors:  Hong Qiu; Ning Li; Jun-Yan Liu; Todd R Harris; Bruce D Hammock; Nipavan Chiamvimonvat
Journal:  Cardiovasc Ther       Date:  2011-04       Impact factor: 3.023

7.  PharmGKB summary: cytochrome P450, family 2, subfamily J, polypeptide 2: CYP2J2.

Authors:  Dorit S Berlin; Katrin Sangkuhl; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-05       Impact factor: 2.089

8.  Impaired transactivation of the human CYP2J2 arachidonic acid epoxygenase gene in HepG2 cells subjected to nitrative stress.

Authors:  Pei H Cui; Andy C Lee; Fanfan Zhou; Michael Murray
Journal:  Br J Pharmacol       Date:  2010-02-24       Impact factor: 8.739

9.  Inhibition of soluble epoxide hydrolase by trans-4- [4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid is protective against ischemia-reperfusion injury.

Authors:  Ketul R Chaudhary; Mohamed Abukhashim; Sung Hee Hwang; Bruce D Hammock; John M Seubert
Journal:  J Cardiovasc Pharmacol       Date:  2010-01       Impact factor: 3.105

10.  Differential effects of soluble epoxide hydrolase inhibition and CYP2J2 overexpression on postischemic cardiac function in aged mice.

Authors:  Ketul R Chaudhary; Beshay N M Zordoky; Matthew L Edin; Nasser Alsaleh; Ayman O S El-Kadi; Darryl C Zeldin; John M Seubert
Journal:  Prostaglandins Other Lipid Mediat       Date:  2012-08-16       Impact factor: 3.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.